US HDMA supports fake drug law

1 April 2009

The USA-based Healthcare Distribution Management Association has issued a message of support for the House of Representatives' Counterfeit Drug  Prevention Act of 2009 (HR 1450), which raises criminal penalties for  producing fake medicines from a range of one to three years imprisonment  to 20 years or more. The group represents wholesalers of prescription  medicines and other pharmacy supplies to 145,000 outlets, including  hospitals, physician offices and pharmacies.

John Gray, the HDMA's president, said: "one of the most effective ways  to deter dangerous counterfeiters is to increase criminal penalties so  that the punishment fits the severity of the crime. I applaud  Representatives Rogers and Green for introducing HR1450. The nation's  primary, full-service distributors pledge to support this legislation  and work toward its speedy enactment."

HR1450 was introduced by Reps Mike Rogers (Republican, Michigan) and  Gene Green (Democrat, Texas) and is to be considered by both the House  Energy and Commerce and House Judiciary Committees.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight